Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia, Followed by a 52-Week Open-label Extension

Next Previous
Trial Profile

Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia, Followed by a 52-Week Open-label Extension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brilaroxazine (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RECOVER; RECOVER-1
  • Sponsors Reviva Pharmaceuticals

Most Recent Events

  • 02 Jun 2025 According to a Reviva Pharmaceuticals media release, virtual investor webcast being held on, June 2, 2025 at 8:00 a.m. EDT regarding the OLE trial data.
  • 02 Jun 2025 Results presented in the Reviva Pharmaceuticals Media Release.
  • 15 May 2025 According to a Reviva Pharmaceuticals media release, Positive topline data from the long-term OLE portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia presented as an oral presentation on March 30th at the 2025 Congress of the Schizophrenia International Research Society (SIRS) in Chicago, Illinois.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top